N1177 is the codename for a nanoparticulate contrast agent under development. N1177 is tested to improve the clinical utility of computed tomography (CT) to diagnose cardiovascular diseases and cancers. N1177 is water insoluble, has an iodine concentration of 67 mg/mL and interacts with activated macrophages. The provider is Nanoscan Imaging, Lansdale, PA.